CSNpharm
Rivastigmine is a acetylcholinesterase inhibitor with IC50 value of 5.5 μM for cholinesterase, used for the treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease.
More Information
Supplier Page
CSNpharm
Rivastigmine tartrate is an AchR inhibitor use for treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease with elimination half-life of 1.5 hours.
More Information
Supplier Page
CSNpharm
Rivastigmine tartrate is an AchR inhibitor use for treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease with elimination half-life of 1.5 hours.
More Information
Supplier Page
CSNpharm
Rivastigmine tartrate is an AchR inhibitor use for treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease with elimination half-life of 1.5 hours.
More Information
Supplier Page
CSNpharm
Rivastigmine tartrate is an AchR inhibitor use for treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease with elimination half-life of 1.5 hours.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
RJR-2403 is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki=26 nM) showing > 1,000 fold selectivity than α7 receptors (Ki= 36000 nM).
More Information
Supplier Page
CSNpharm
RJR-2403 is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki=26 nM) showing > 1,000 fold selectivity than α7 receptors (Ki= 36000 nM).
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
RMI 10874 is a tilorone analogue. Tilorone is a small-molecule, orally bioavailable antiviral agent. RMI 10874 completely abolishes lung colonization of an H-2 negative (GR9.B9) MCA-induced fibrosarcoma clone.
More Information
Supplier Page
CSNpharm
RMI 10874 is a tilorone analogue. Tilorone is a small-molecule, orally bioavailable antiviral agent. RMI 10874 completely abolishes lung colonization of an H-2 negative (GR9.B9) MCA-induced fibrosarcoma clone.
More Information
Supplier Page
CSNpharm
RMI 10874 is a tilorone analogue. Tilorone is a small-molecule, orally bioavailable antiviral agent. RMI 10874 completely abolishes lung colonization of an H-2 negative (GR9.B9) MCA-induced fibrosarcoma clone.
More Information
Supplier Page
CSNpharm
RN-1734 is selective antagonist of the TRPV4 channel, completely antagonizes 4αPDD-mediated activation of TRPV4 with comparable, low micromolar IC50 values for all three species (hTRPV4: IC50 = 2.3 μM, mTRPV4: IC50 = 5.9 μM, rTRPV4: IC50 = 3.2 μM).
More Information
Supplier Page
CSNpharm
RN-1734 is selective antagonist of the TRPV4 channel, completely antagonizes 4αPDD-mediated activation of TRPV4 with comparable, low micromolar IC50 values for all three species (hTRPV4: IC50 = 2.3 μM, mTRPV4: IC50 = 5.9 μM, rTRPV4: IC50 = 3.2 μM).
More Information
Supplier Page
CSNpharm
RN-1734 is selective antagonist of the TRPV4 channel, completely antagonizes 4αPDD-mediated activation of TRPV4 with comparable, low micromolar IC50 values for all three species (hTRPV4: IC50 = 2.3 μM, mTRPV4: IC50 = 5.9 μM, rTRPV4: IC50 = 3.2 μM).
More Information
Supplier Page
CSNpharm
RN-1734 is selective antagonist of the TRPV4 channel, completely antagonizes 4αPDD-mediated activation of TRPV4 with comparable, low micromolar IC50 values for all three species (hTRPV4: IC50 = 2.3 μM, mTRPV4: IC50 = 5.9 μM, rTRPV4: IC50 = 3.2 μM).
More Information
Supplier Page
CSNpharm
RN-1734 is selective antagonist of the TRPV4 channel, completely antagonizes 4αPDD-mediated activation of TRPV4 with comparable, low micromolar IC50 values for all three species (hTRPV4: IC50 = 2.3 μM, mTRPV4: IC50 = 5.9 μM, rTRPV4: IC50 = 3.2 μM).
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
Ro 31-8220 mesylate is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively.
More Information
Supplier Page
CSNpharm
Ro 31-8220 mesylate is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively.
More Information
Supplier Page
CSNpharm
Ro 31-8220 mesylate is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively.
More Information
Supplier Page
CSNpharm
Ro 31-8220 mesylate is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
Ro 48-8071 Fumarate is an inhibitor of Oxidosqualene cyclase (OSC) with IC50 of 6.5 nM, also inhibits Ebola virus (EBOV) cell entry with IC50 of 1.74 μM and blocks cholesterol synthesis in HepG2 cells.
More Information
Supplier Page
CSNpharm
Ro 48-8071 Fumarate is an inhibitor of Oxidosqualene cyclase (OSC) with IC50 of 6.5 nM, also inhibits Ebola virus (EBOV) cell entry with IC50 of 1.74 μM and blocks cholesterol synthesis in HepG2 cells.
More Information
Supplier Page
CSNpharm
Ro 48-8071 Fumarate is an inhibitor of Oxidosqualene cyclase (OSC) with IC50 of 6.5 nM, also inhibits Ebola virus (EBOV) cell entry with IC50 of 1.74 μM and blocks cholesterol synthesis in HepG2 cells.
More Information
Supplier Page